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Abstract
Multifunctional folate-targeted cationic magnetoliposomes (FTMLs) have been prepared with co-
encapsulated doxorubicin (DOX) and anionic superparamagnetic iron oxide (SPIO) nanoparticles
with 5 nm γ-Fe2O3 cores and 16 nm hydrodynamic diameters. Nanoparticle encapsulation (89%)
was confirmed by cryogenic transmission electron microscopy, and the presence of the oppositely
charged nanoparticles did not cause liposome aggregation. The FTMLs had an average diameter of
174 ± 53 nm and existed as unilamellar and cup-shaped liposomes, which was attributed to
dissimilar lipid packing parameters and the presence of PEG-lipids. A 3-fold increase in DOX
release was achieved over two hours when the encapsulated SPIO nanoparticles were heated by an
alternating current electromagnetic field operating at radiofrequencies (RF). Results with human
cervical cancer cells (HeLa), which have been shown to exhibit high folate receptor (FR)
expression, confirmed FTML surface binding and cellular uptake. In contrast, no uptake was
observed for lower FR-expressing human breast carcinoma cells (ZR-75-1).
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Introduction
Magnetoliposomes, which are self-assembled liposomes containing encapsulated magnetic
nanoparticles, are one promising example of a multifunctional liposome-nanoparticle
assembly (LNA). 1-4 Their multi-functionality stems from the ability to guide them in vivo
using magnets, to utilize the particles as image contrast agents, to provide hyperthermia
treatment by heating the nanoparticles in an alternating current electromagnetic field at
radiofrequencies (i.e. RF-heating), and to provide liposomal drug delivery (see reviews by
De Cuyper and Joniau5 and Soenen et al6). A lesser-explored approach related to this work
is utilizing localized RF-heating within the magnetoliposomes for controlled drug
release.7-10 Headgroup-functionalized lipids with targeting or stabilizing moieties (e.g.
polyethylene glycol or PEG) can incorporated within the bilayer to target specific receptors
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overexpressed on cancer cell surfaces and to increase bioavailability, respectively. Cationic
lipids can also be used to bind anionic molecules or aid cell uptake.11, 12
Magnetoliposomes are promising, but do have shortcomings. There is evidence that
inorganic nanoparticles, including iron oxide, can inhibit cell function.13, 14 Thus, it is
advantageous to reduce the concentration of encapsulated nanoparticles and maximize
cellular targeting. This presents a challenge as high nanoparticle concentrations are needed
to, for example, achieve sufficient MRI imaging contrast, hyperthermia, and magnetic
guidance. For hyperthermia or RF-induced drug release, the energy absorbed by the particles
is converted into heat through magnetic losses via Brown and Néel relaxation. To achieve
liposome release via permeabilization at low nanoparticle concentrations or low
electromagnetic field strengths, the heating should be localized near the bilayer surface. This
can be achieved by chemically or physically binding the nanoparticles to the bilayer.
We report the design and characterization of folate-targeted cationic magnetoliposomes
(FTMLs) containing encapsulated doxorubicin (DOX; Figure 1). Folate receptor (FR) is
overexpressed in many cancer cells compared to healthy cells and exhibits a high affinity for
folate conjugates (Kd ∼100pM).15, 16 FTMLs were prepared based on the premise that
electrostatic attraction between the cationic lipids and anionic superparamagnetic iron oxide
(SPIO) nanoparticles would enhance physical bilayer-nanoparticle binding and, with RF-
heating, this binding would trigger transbilayer release. This compliments our recent work
on focused nanoparticle heating achieved by embedding small hydrophobic SPIO
nanoparticles within liposomal bilayers.9 SPIO nanoparticles with 16 nm hydrodynamic
diameters were selected for their high curvature, which favored nanoparticle-liposome
binding rather than the formation of supported lipid bilayers. The objective of this work was
to characterize FTML structure and morphology, and to demonstrate RF-tiggered DOX
release and cellular uptake by cervical cancer cells (HeLa).
Experimental
Materials
Cholesterol and the lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-
dipalmitoyl-3-trimethylammonium-propane (DPTAP), 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DPPE), 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] (PEG750-
DMPE), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene
glycol)-2000] (Fol-PEG2000-DSPE) were purchased from Avanti Polar Lipids (Alabaster,
AL). Doxorubicin (DOX) was purchased from Sigma-Aldrich (St. Louis, MO). Phosphate
buffered saline (PBS, 1 or 10×, pH 7.4) was prepared using sterile deionized ultrafiltered
water obtained from a Millipore Direct 3-Q purification system (Billerica, MA).
Maghemite SPIO nanoparticles (5 nm γ-Fe2O3 cores) were purchased from Ocean
NanoTech (Springdale, AR). The particle surfaces contained oleic acid capped by an
amphiphilic polycarboxylate coating that was formed by hydrolyzing poly(maleic
anhydride-alt-1-octadecane) (Figure 2C).17, 18 The nanoparticles had a hydrodynamic
diameter of 16 ± 3 nm, based on dynamic light scattering, and a zeta potential of -39.8 mV
(Malvern Instruments Zetasizer Nano ZS, results not shown).
Folate-targeted cationic magnetoliposome (FTML) formation
FTMLs were prepared at 10 mM total lipid by thin film hydration followed by extrusion
through double-stacked polycarbonate membranes with 200 nm pore diameters. The bilayer
components used to prepare the FTMLs are shown in Table 1. In this process, aliquots of the
lipids and cholesterol dissolved in chloroform were pipetted into test tubes to provide the
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desired composition. Nitrogen gas was flowed over the samples to evaporate the chloroform
and leave dry lipid films. Residual solvent was removed from these films by vacuum drying
at 635 mm Hg for 2 h. The dry lipid films were hydrated at room temperature with either
10× PBS buffer (FTLs) or 10× PBS containing both SPIO nanoparticles and DOX (FTMLs).
SPIO nanoparticles were encapsulated at a concentration of 1 μM (6×1014 particles ml-1 or
0.19 mg γ-Fe2O3 ml-1) and DOX was encapsulated at 2 μM. Samples were dialyzed for 24 h
using 1000 kDa tubular cellulose acetate membranes with stirring and frequent media
exchange to remove unencapsulated DOX. DOX removal after dialysis was determined by
fluorescence spectroscopy (Perkin Elmer LS55) against a calibration curve of DOX in PBS.
A third sample was prepared within the FR targeting lipid (MLs; no Fol-PEG2000-DSPE) for
cellular uptake studies. All samples were blanketed with nitrogen, stored in the dark at room
temperature, and used within 2 weeks of preparation.
Nanoparticle encapsulation efficiency was determined immediately after sample preparation
using a centrifugation procedure similar to that of Pradhan et al.19 However, in our case the
cations in PBS screened the repulsive charges between unencapsulated nanoparticles and led
to aggregation. The sample was centrifuged at 1000 g for 10 min at 4 °C. The precipitate
containing nanoparticle aggregates was resuspended in DI water, digested in nitric acid, and
analyzed by inductively coupled plasma mass spectrometry (ICP-MS, Thermo Electron X
Series, Waltham, MA). The reported encapsulation efficiency is based on the 57Fe isotope.
Cryogenic transmission electron microscopy (cryo-TEM)
The size and structure of the FTLs and FTMLs were analyzed by cryo-TEM (JEOL
JEM-2100F, Peabody, MA). Samples were prepared at room temperature and 100% relative
humidity using a Vitrobot (FEI Company), which is a PC-controlled robotic system for
sample vitrification. Quantifoil grids were used with 2 μm carbon holes on 200 square mesh
copper grids (Electron Microscopy Sciences, Hatfield, PA). To prepare a cryo-TEM sample
for analysis, a grid was immersed in the FTL or FTML sample reservoirs at room
temperature, blotted with blotting paper to reduce film thickness and draw the sample into
the grid, and vitrified in liquid ethane. The sample was then transferred to liquid nitrogen for
storage. Imaging was performed at 200 kV in a stage cooled by liquid nitrogen (Model 915,
Gatan Inc., Pleasonton, CA). Size analysis was performed using ImageJ software using FTL
or FTML populations of 50 or greater.
Fluorescence anisotropy
The fluidity of FTML bilayers was examined by fluorescence anisotropy (Perkin Elmer LS
55) using the hydrophobic bilayer probe diphenylhexatriene (DPH), which was added to the
lipid mixture at a 500:1 lipid to DPH ratio prior to thin film hydration. Anisotropy was
conducted at 1 μM DPPC from 10 to 70 °C at a rate of 1°C min-1 under continuous mixing.
Steady-state DPH anisotropy within the DPPC bilayer was determined at λex = 350 nm and
λem = 452 nm using the expression <r> = (IVV - IVH)/(Ivv + G×IVH) where I represents the
emission intensity, the subscripts V and H represent the vertical and horizontal orientation of
the excitation and emission polarizers, and G = IHV/IHH accounts for the sensitivity of the
instrument towards vertically and horizontally polarized light.20
Doxorubicin release
DOX release was examined with and without RF-heating using dialysis. FTMLs were
loaded at 0.5 ml into 1.5 ml Flotalyzer™ dialysis tubes with 8 kDa molecular weight cut-off.
The dialysis tubes were immersed in 20 ml 10× PBS sampling reservoirs. Dialysate sample
volumes of 10 μl were collected every 15 min and DOX concentration was measured by
fluorescence spectroscopy against a calibration curve (Perkin Elmer LS55, Waltham, MA).
Fresh PBS was added to the reservoir to maintain 20 ml. For RF-heating, a 2.54 cm copper
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heating coil containing 3 loops was placed around the sampling reservoir. Heating was
conducted for 2 h at 250 A and 287 kHz using a 1 kW Hotshot™ from Ameritherm Inc.
(Scottsville, New York).
This produced an electromagnetic field of 5.9×105 kA m-1 s-1 based on the product Hf where
H is the field amplitude (current × number of coils per length) and f is the frequency.
Heating was stopped briefly to retrieve a sample and makeup the dialysate reservoir volume.
It is important to note that the dialysis setup was made entirely from plastic or glass, and
contained no metal that could have been heated by the field.
The specific absorbance rate (SAR) of the SPIO nanoparticles was determined in DI water at
a concentration of 3 mg ml-1 using a fiber optic temperature probe (Luxtron). SAR was
determined from the initial slope of temperature as a function of time using the expression
ΔT / Δt = SARmNP /(c̄p mV) where mN and mV are the mass of the nanoparticles and sample
volume, respectively, and c̄p = ϕcp,N + (1 − ϕ)cp,F is the average heat capacity based on the
nanoparticle volume fraction in the sample, ϕ. The field was identical to that of the DOX
release experiment.
In vitro HeLa cell uptake studies
HeLa and ZR-75-1 (human breast carcinoma) cell lines (American Type Culture Collection,
Manassas, VA) were maintained at 37 °C, under humidified air with 5% CO2, in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 5% (v/v) fetal bovine serum (FBS),
100 U mL-1 penicillin G, 100 μg mL-1 streptomycin, 2 mM GlutaMAX, 0.15% (w/v)
sodium bicarbonate, 1 mM sodium pyruvate, 10 mM HEPES buffer, and 100 μM non-
essential amino acids (cell culture media and additives were from Invitrogen/Life
Technologies, Carlsbad, CA). Cells in maintenance medium were trypsinized and seeded
into 6-well culture plates at optimum confluence. Incubations were conducted at 1 μM
FTMLs or 1 μM MLs(lipid basis) in serum-containing maintenance medium for 30, 60, 120,
or 180 min. At these time points, cells were washed in 1× PBS to remove free FTMLs or
MLs. Cellular uptake was monitored by fluorescence microscopy on an inverted Nikon
microscope under 200× or 400× magnification. Uptake experiments were conducted in
triplicate.
Folate receptor 1 (FOLR1) expression
FOLR1 expression profile was examined by quantitative PCR. Briefly, total RNA was
isolated from cell lines using Trizol reagent or PureLink columns (Invitrogen Corp.,
Carlsbad, CA) and aliquots were subjected to reverse transcription to make cDNA using
High Capacity cDNA kit (Applied Biosystems). FOLR1 and beta-actin specific primers
were designed using the webtool QPrimerDepot (http://primerdepot.nci.nih.gov).21
Quantitative real-time PCR was performed using SYBR Green master mix, cDNA and gene-
specific primers (Applied Biosystems) and FOLR1 expression was normalized to beta-actin
expression among cell lines.
Results
FTL and FTML structure and stability
Co-localization of NBD-PE lipid (green; Figure 1A) and DOX (red; Figure 1B) within
FTMLs was verified by fluorescence microscopy. The results show that there was no
measurable DOX present outside of the liposomes and that unencapsulated DOX was
successfully removed by dialysis. Removal of 96.5% of the unencapsulated DOX was
confirmed after dialysis. With respect to nanoparticle encapsulation, an encapsulation
efficiency of 89% was estimated based on ICP-MS. It should be noted that encapsulation
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efficiency accounts for nanoparticles encapsulated within the aqueous FTML core and
bound to the external FTML bilayer surface.
Cryo-TEM analysis showed that FTL and FTMLs exhibited similar size and structure, which
indicates that DOX and SPIO nanoparticle encapsulation or binding did not affect FTML
formation (Figures 2A and 2B, respectively). Nanoparticle encapsulation was observed
within FTMLs (Figure 2B-4, B-5, black arrows). However, encapsulation was
heterogeneous as evident from (i) liposomes containing no nanoparticles, (ii) FTMLs
containing single nanoparticles, and (iii) FTMLs containing nanoparticle aggregates. The
dark structure shown in Figure 2B-5 (black arrow) may depict an unencapsulated
nanoparticle aggregate or lipids in cubic ice.22 If it was an aggregate, this was the only one
observed throughout the TEM grid, consistent with the high encapsulation efficiency (89%),
and would have likely formed due to van der Waals and magnetic attraction23 coupled with
charge screening of internanoparticle electrostatic repulsion. If present, unencapsulated
nanoparticle aggregates could not have been removed by dialysis.
Three distinct liposome structures were observed by cryo-TEM and fluorescence
microscopy; large unilamellar liposomes, smaller liposomes encapsulated within larger
liposomes, and cup-shaped liposomes (Figure 2A, B). Consistency between cryo-TEM and
fluorescence images confirms that the structures were not artifacts of cryo-TEM sample
preparation. The cup ‘rims’ can be clearly seen in the images, which suggests that the cup-
shaped liposomes formed by single unilamellar liposomes collapsing within themselves and/
or the fusion of inner (encapsulated) liposomes to outer (encapsulating) liposomes. The
average diameter of all the structures observed was 174 ± 53 nm, consistent with membrane
extrusion. However, the presence of larger liposomes up to approximately 300 nm suggests
that the liposomes restructured and/or fused during post-extrusion. Fluorescence microscopy
images also show liposome cupping and what appears to be budding (Figure 2C).
In addition to size and structure, bilayer fluidity is an important component to liposome
function. Fluorescence anisotropy results on the FTMLs show that DPH anisotropy, <r>,
increased with temperature up to 70 °C (Figure 3). The melting temperature (Tm) of the
FTML bilayers was estimated at 1 °C based on the weighted average of all components
(Table 2). Hence, this result indicates that the fluid bilayer become more ordered, or less
fluid, with increasing temperature.
FTML doxorubicin release via electromagnetic heating
Dialysis was conducted with and without RF-heating for 2 h to determine the extent of
spontaneous and nanoparticle-mediated DOX release from the FTMLs. Results are
expressed as normalized release based on fluorescence intensities, IRF/I0, to demonstrate the
apparent RF-triggered release relative to spontaneous leakage (Figure 4). With RF-heating, a
3-fold increase in DOX release was observed from 45 to 90 min. The lag from 0 to 45 min is
attributed the time it took DOX to diffuse through the dialysis membrane and into the
dialysate after being released from the FTMLs.
FTML uptake by HeLa cells in vitro
The uptake of FTMLs or MLs (no FR targeting lipid) at 1 μM was examined as a function of
time by microscopy in plated HeLa (Figure 5) and ZR-75 cell lines (Figure S1,
Supplemental Material). In this case the assemblies did not contain DOX because it is
cytotoxic. Corresponding brightfield and fluorescence images are shown to provide a
qualitative comparison of cellular uptake as a function of time. HeLa cell uptake was
observed for both FTMLs and MLs. Based on the observed fluorescence intensity, the
degree of uptake was similar up to 120 min. However, at 180 min the images depict greater
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of the FR-targeted FTMLs compared to the MLs. Closer examination at 60 min and 180 min
(Figure S2, Supplemental Material) indicate that at 60 min the FTMLs were bound to the
cell surface, while at 180 min they were internalized. In comparison, no FTML or ML
uptake was observed in ZR-75-1 cells. This is result is consistent with FOLR1 expression
results, where HeLa cells showed 42.5-fold greater expression than ZR-75-1.
Discussion
There are a number of reports on FR targeting using liposomes containing folate-lipid
conjugates.15, 24-28 Closely related to this work is that of Pradhan et al,10 who designed
magnetoliposomes with co-encapsulated 60 nm magnetic particles and DOX. They were
composed of dipalmitoylphosphatidylcholine (DPPC), Chol, PEG2000-DSPE, and Fol-
PEG2000-DSPE, and exhibited a melting temperature near 41 °C. HeLa cell uptake was
demonstrated, similar to our work, and reductions in cell viability were attributed to a
synergistic effect of DOX and hyperthermia.
In this work the PEG linker associated with the folate ligand (PEG2000) was longer than that
of the stabilizing PEG-lipid (PEG750). This was chosen to eliminate steric interference of
folate binding, which has been demonstrated for stabilizing and folate targeting lipids with
the same PEG linker.29 Second, the FTMLs were designed to be in the fluid phase at room
temperature. Kawano et al28 have shown that greater bilayer fluidity enhances the antitumor
activity of FR targeting liposomes. Third, the FTMLs have been prepared with the intent of
orienting small, anionic SPIO nanoparticles near the bilayers via electrostatic attraction.
Cryo-TEM micrographs showed nanoparticle and nanoparticles aggregates near FTML
bilayers, presumably aided by this attraction.
Cryo-TEM revealed a number of FTML structures. Cup-shaped liposomes, denoted by white
arrows in Figure 2A and B, are interesting and may have been formed by curvature strain
caused by lipid packing (Table 2) and/or the fusion of inner to outer liposomes. At the
concentrations employed (< 5 mol%), PEG750-DMPE (4 mol%) and Fol-PEG2000-DSPE
(0.1 mol%) likely extended from the liposome/water interface in mushroom configurations
and did not interact laterally.30, 31 The length can be calculated from Lmush = aN3/5 where a
is the monomer length (0.35 nm) and N is the degree of polymerization (17 and 46 for 750
and 2000 MW PEG, respectively).30 From this equation, PEG750-DMPE and Fol-PEG2000-
DSPE extended approximately 1.9 nm and 3.5 nm from the liposome surfaces, respectively.
It has been shown that conjugated PEG does not affect lipid packing parameters (PP) at or
below 4 mol%. The major component, DOPC (47.5 mol%), had a PP = 1.08 and the cationic
lipid, DPTAP (18.9 mol%), had a PP = 0.91 (average PP = 1.08).32 Conical lipids (i.e. PP <
1) in heterogeneous liposomes can phase separate into regions that exhibit lower bending
elasticity and, hence, adopt higher curvature.33 In the FTMLs, the lower PP and higher
melting temperature of DPTAP relative to DOPC may have caused it to phase separate into
high curvature regions that supported the cup rims. This would have been aided by charge
screening of repulsive DPTAP headgroup interactions at the high electrolyte concentration
(10× PBS). DPTAP phase separated would have increased the average PP of the remaining
bilayer (PP ∼ 1.1) to favor negative curvature, which was observed on the inner cup
bilayer.34 It is important to note that the observed structures are likely dynamic and may
undergo a number of shape fluctuations.
In addition to curvature strain, fusion may have been promoted by the presence PEG-lipids,
and the fusion of inner to outer liposomes may have contributed to liposome cupping. As the
inner liposomes approached the outer, the point of impending contact may have been devoid
of PEG which produces an osmotic pressure that drives liposome aggregation.35 Yang et
al36 have shown that large unilamellar liposomes can aggregate with 1-2 mol% PEG-lipid
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and that curvature stress within the bilayers, inferred in this work from the presence of cup-
shaped liposomes, can lead to liposome fusion. Furthermore, Varga et al37 have shown that
PEG-lipids (in their case PEG2000-DSPE) exhibit an asymmetric distribution across the
bilayer (75% outside), which can also enhance curvature strain. While we did not observe
aggregation, it is possible that PEG-lipids produced additional curvature strain within the
FTML bilayers and caused fusion. Budding, observed by cryo-TEM and fluorescence
microscopy, is also driven by these factors.
Despite the evidence of FTML restructuring, qualitative evidence suggests that this did not
compromise their stability. This is intuitive considering that the PEG-lipids would provide
steric stabilization despite being involved in restructuring. Fluorescence microscopy showed
that the FTMLs remained dispersed in 10× PBS. This is consistent with cryo-TEM analysis,
which showed no FTML aggregation. Furthermore, there was no evidence of sedimentation
after two weeks of storage at room temperature (results not shown). This is an important
observation as it demonstrates that the addition of oppositely charged nanoparticles to
cationic liposomes does not cause heteroaggregation.
Anisotropy results confirmed that the FTMLs existed in a fluid state (as expected).
However, the increase in anisotropy with temperature reflected a decrease in local bilayer
fluidity that can be attributed to the effects of PEG on lipid hydration. It is known that water
becomes a ‘poorer’ solvent for PEG with increasing temperature, which increases PEG
hydrophobicity.38 In turn, increasing PEG hydrophobicity would also reduce lipid hydration.
The anisotropy results are consistent with previous work that has shown that the inclusion of
PEG-lipid in fluid liposomes (below 8 mol%) leads to greater adiabatic compressibility and
reduced lipid hydration with increasing temperature.39 Changes in bilayer compressibility
would have also enhanced curvature strain.
While cryo-TEM results showed that nanoparticle encapsulation had little affect on FTML
structure, DOX release results demonstrated that RF-heating of the nanoparticles did played
an active role in triggering release. However, we cannot directly attribute this to nanoparticle
heating due to the fact that the average Tm was 1 °C. Hence, the lipid bilayers were in a fluid
state and heating did not trigger a phase transition. Based on a measured SAR value of 98.7
W g-1 γ-Fe2O3, a temperature change of 9 °C was estimated over 120 min (the duration of
the release experiment). However, SAR is based on the initial heating slope and this
temperature change represents a maximum under adiabatic conditions. Furthermore, this
temperature change would have caused only a minor decrease in bilayer fluidity (Figure 3).
Recent theoretical40 and experimental41, 42 work has shown that the temperature difference
between a nanoparticle surface its surroundings due to electromagnetic field heating (light or
RF) is negligible due to rapid heat dissipation from the nanoparticle surface. While FTML
heating may have contributed to DOX release, mechanically-induced release due to the
rotation or oscillation of nanoparticles bound to the lipid bilayer may be more likely.
It is important to note that the FTMLs were designed as a base structure for combined
targeting and controlled drug release via an external RF trigger. The lipid composition,
nanoparticle loading, drug concentration, or RF field conditions can be modified to optimize
performance. Preliminary results demonstrate that FTMLs are capable of binding to and
being internalized by FR-expressing HeLa cells. Uptake through FR binding is attributed to
FR-mediated endocytosis,16 which was confirmed by comparing FTML verses ML uptake,
and HeLa verses ZR-75-1 uptake. Future work is needed to quantify the extent of binding
and uptake, and FTML stability in serum-containing medium.
The therapeutic efficacy of nanoscale assemblies is tied to the ability to (i) prevent
premature drug release before reaching a target site, (ii) initiate or “trigger” drug release on
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demand once a target site has been reached, and (iii) control the rate of drug release to the
target site. This work has demonstrated that FTMLs can be designed with these properties
by co-encapsulating DOX and SPIO nanoparticles. The FTMLs displayed solution structures
consistent with lipid packing parameters and the effects of PEGylated lipids on liposome
structure. Fluorescence anisotropy results depicted a decrease in bilayer fluidity with
increasing temperature, consistent with greater PEG hydrophobicity and lipid dehydration.
While FTMLs did exhibit colloidal stability over the conditions examined, additional work
is required to assess the long-term stability, and the effects of biologically relevant serum
protein concentrations and increased nanoparticle loading on this stability. Furthermore,
thought nanoparticle encapsulation was achieved, optimization is required to improve the
extent and efficiency of encapsulation. This, ultimately, can be used to control the drug
release properties via RF-heating.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Schematic of FTMLs containing co-encapsulated doxorubicin (DOX, red) and SPIO
nanoparticles (gray). The liposome components include (in order of decreasing molar
concentration) zwitterionic 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cationic 1,2-
dipalmitoyl-3-trimethylammonium-propane (DPTAP), cholesterol (Chol), PEGylated 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750]
(PEG-DMPE), fluorescent 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-
nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DPPE), and folate-modified 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (Fol-PEG2000-
DSPE). Fluorescence microscopy images of FTMLs in PBS (400× magnification) are shown
containing NBD-DPPE (green, A) and encapsulated DOX (red, B).
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Figure 2.
Cryo-TEM micrographs of (A) FTLs without encapsulated DOX and (B-1 to B-5) FTMLs
containing encapsulated DOX and SPIO nanoparticles. Both samples were prepared by thin
film hydration in 10× PBS (pH 7.4) followed by membrane extrusion at 200 nm. The 200
nm scale bar is common to A and B-1 to B-3, and the 500 nm scale bare is common to B-4
and B-5. White arrows denote cup-shaped liposomes containing a visible pore or mouth and
black arrows denote SPIO nanoparticles and nanoparticle aggregates. The square region
denotes liposome budding. Representative magnified fluorescence microscopy images at
1000× magnification (bottom) of FTML cupping and budding.
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Figure 3.
Fluorescence anisotropy of DPH (<r>) in FTML bilayers as a function of increasing
temperature. The can rate was 1 °C min-1.
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Figure 4.
DOX release from FTMLs based on normalized fluorescence intensities with (IRF) and
without (I0) RF-heating for 120 min at a field strength of 5.9×105 kA m-1 s-1.
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Figure 5.
Brightfield and fluorescence micrographs of in vitro HeLa cell uptake of FTMLs or MLs
without DOX (200× magnification) incubated for 30, 60, 120, or 180 min. The green
fluorescence is from NBD-DPPE.
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Table 1
Bilayer composition of foltate receptor-targeting magnetoliposomes (FTMLs).
Function Membrane component Headgroup
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC, 785.6 MW) zwitterionic (+1/-1)
Base bilayer composition 1,2-Dipalmitoyl-3-trimethylammonium-propane (DPTAP, 645.5 MW) cationic (+1)
47.5% DOPC
18.9% DPTAP
28.5% Chol
Cholesterol (Chol, 386.7 MW) n/a
Fluorescent lipid (1%) 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DPPE,
871.5 MW)
anionic (1-)
Stabilizing lipid (4%) 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] (PEG750-
DMPE, 1414.9 MW)
anionic (1-)
Targeting lipid (0.1%) 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (Fol-PEG2000-
DSPE, 3230.9 MW)
anionic (2-)
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Table 2
Lipid melting temperatures and packing parameters (PP).
Membrane component % Tm (°C) PP
DOPC 47.5 -20 1.0824
DPTAP 18.9 42 0.9125
Chol 28.5 n/a 1.2126
NBD-DPPE 1.0 63a 1.04b
PEG750-DMPE 4.0 50a 1.04b
Fol-PEG2000-DSPE 0.1 74a 1.0427
molar average 1 1.08
a
based on Tm of DPPE, DMPE, and DSPE.
b
Calculated PP based on DSPE, PP = vc(alc)−1, where vc is the volume of the carbon tails, a is the area per lipid, and lc is the length of the
carbon tails.
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